Compal to Unveil Next-Generation AI-HPC NVIDIA MGX-Based Servers at GTC 2025
SAN JOSE, Calif., March 14, 2025 /PRNewswire/ -- Compal Electronics (Compal; Stock Ticker: 2324.TW), a global leader in IT and computing solutions, is set to participate in NVIDIA GTC 2025, where it will showcase its latest advancements in AI-HPC GPU server solutions. Taking place on March 18, 2025, at the San Jose Convention Center, GTC 2025 is the premier platform for breakthrough AI, high-performance computing, and enterprise innovations.
At this highly anticipated event, Compal will unveil several high-performance GPU servers focused on optimizing AI training, accelerating data center operations, and supporting large-scale HPC applications. Attendees will have the opportunity to preview GPU servers based on the NVIDIA MGX architecture, along with other high-density computing solutions designed for next-generation computing environments. In addition, Compal has already started shipping servers equipped with the NVIDIA GH200 Grace Hopper™ Superchip, with expectations for larger shipment volumes in the future, reflecting strong market demand and confidence.
Compal stated 'GTC 2025 is the ideal platform to showcase our latest AI-HPC innovations, and we are honored to collaborate with industry-leading partners, including power solutions expert AcBel Polytech Inc., chassis leader Chenbro, software development pioneer Infinitix, globally renowned memory manufacturer Samsung Electronics, and ZutaCore®, a leader in zero-emissions data center cooling with HyperCool® technology.' Additionally, Compal's partners will present keynote speeches at the Compal booth, sharing insights into cutting-edge technologies and innovative solutions, as well as exploring future trends in high-performance computing.
Expanding AI and 5G Integration
Leveraging its deep expertise in 5G RF, PHY layer, and Open Radio Access Network (O-RAN), Compal continues to innovate in wireless communication technology. Recently, Compal launched the AI server SX220-1N, which integrates NVIDIA Aerial with 5G base stations to create an AI RAN solution. By utilizing AI technology, this solution enhances network intelligence and efficiency, enabling cognitive automated testing for 5G systems, improving spectrum utilization, and expanding coverage, ultimately reducing operational costs.
As AI applications continue to drive industry transformation, Compal is dedicated to building cutting-edge GPU server architectures to help businesses efficiently handle compute-intensive workloads. Attendees at GTC 2025 will have the opportunity to explore Compal's latest breakthroughs and gain insights into next-generation AI infrastructure.
In addition to debuting at GTC 2025, Compal will also showcase its advanced GPU servers at the CloudFest event in Europe, highlighting its global innovation in AI and HPC solutions. For European audiences who are unable to attend GTC 2025, CloudFest offers an alternative opportunity to explore Compal's latest AI and HPC server technologies.
About Compal
Founded in 1984, Compal is a leading manufacturer in the notebook and smart device industry, creating brand value in collaboration with various sectors. Its groundbreaking product designs have received numerous international awards. In 2024, Compal was recognized by CommonWealth Magazine as one of Taiwan's top 6 manufacturers and has consistently ranked among the Forbes Global 2000 and Fortune Global 500 companies. In recent years, Compal has actively developed emerging businesses, including cloud servers, auto electronics, and smart medical, leveraging its integrated hardware and software R&D and manufacturing capabilities to create relevant solutions. More information on Compal server, please visit
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
SHANGHAI, June 1, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel ("satri-cel", CT041) (a Claudin18.2-specific autologous CAR T-cell product candidate) in patients with Claudin18.2-positive, advanced gastric/gastroesophageal junction cancer refractory to at least two prior lines of treatment, have been published in The Lancet and were orally presented at the 2025 ASCO Annual Meeting. Further details have been posted on the corporate website The article in The Lancet was titled "Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial". Full article available at: The oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled "Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01)". Professor Lin Shen from Beijing Cancer Hospital, the principal investigator of this study, said, "The CT041-ST-01 trial represents the world's first randomized controlled clinical study of CAR-T cell therapy for solid tumors. In patients with heavily pretreated, advanced gastric/gastroesophageal junction cancer who have extremely limited treatment options and poor prognosis, satri-cel has demonstrated breakthrough efficacy with significant clinical benefits, including much improved progression-free survival (PFS), overall survival (OS), and tumor response rates. This brings new hope to patients with otherwise medically untreatable conditions. We are further exploring satri-cel's potential in adjuvant settings and as first-line sequential therapies, aiming to intervene earlier in the disease course, extend patients' survival, and ultimately pursue potential cures." Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "We are honored that the CT041-ST-01 study results were published in The Lancet—a premier, global medical journal—and presented at the 2025 ASCO Annual Meeting. The positive result of this randomized controlled trial marks a major milestone in solid tumor CAR-T therapy. These achievements are a testament to the whole research team's years of dedication, and we extend our deepest gratitude to patients and their families for their trust and participation. This year, satri-cel has been granted Breakthrough Therapy Designation and Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. We plan to submit a New Drug Application (NDA) for satri-cel to the NMPA this month and anticipate its approval as the world's first commercially available CAR-T product for solid tumors, bringing benefits to patients." About Satri-cel Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib clinical trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595). Satri-cel has been granted Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in May 2025. Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA in September 2020 for the treatment of G/GEJA. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics
Yahoo
10 hours ago
- Yahoo
HORIZON PETROLEUM PROVIDES AN OPERATIONS UPDATE OF ITS PREPARATION FOR FIRST PRODUCTION IN POLAND
CALGARY, AB, June 1, 2025 /PRNewswire/ - Horizon Petroleum Ltd. (the "Company" or "Horizon") (TSXV: HPL) (FRA: HPM) (Tradegate: HPM) is pleased to provide an operations update on progress made towards first production from its cornerstone Lachowice gas development in the Bielsko-Biala concession, southern Poland. David Winter, CEO of the Horizon commented: " We are pleased with the continuing progress in our operations towards first production from the Lachowice 7 well. Board and Management recognise the efforts of our operating team in Poland in ensuring that the initial development program is executed as planned. We also recognise the very positive relationships that we enjoy with our neighbours at Lachowice, and the positive contributions from our contractors, local authorities and government. We look forward to our continuing work with all stakeholders and will update shareholders as the initial development program progresses". Assuming a successful workover result, gas and/or electrical power sales from the Lachowice 7 (L7) well will provide the Company with its first cashflow and will provide a long-term test of the production performance of the naturally fractured, Devonian aged, limestone and dolomite reservoirs in the L7 well. Preparatory work for the L7 workover is progressing on schedule: The Environmental Impact Assessment (EIA) Permit for the L7 workover has been approved by the Ministry of Climate and the Environment (the "Ministry"). With the funds from the recent successful debenture financing, long lead time materials and services have been sourced and ordered with expected deliveries in August and September. These materials include the tubing, wellhead and completion equipment. The Company has received confirmation from its electrical contractor that the local utility company will move the power line that crosses the L7 wellsite by the end of June. Final civil engineering design for the wellsite and access road has been completed and tendering for the construction works to be awarded in the next 3-4 weeks. Wellsite and access road construction to commence in July once the above-mentioned electricity line has been moved. The Company is working with a local service provider to choose the appropriate rig for the workover, now scheduled to commence in September with long-term production testing of the well in October. Early Production System (EPF) The Company continues the work towards finalizing the early production scheme for the initial development at the L7 well following the workover and testing. As previously disclosed, the Company contracted a local electrical engineering company and a mechanical engineering company to review options to monetize gas production from the initial development at L7 and the full field development Lachowice gas field. The reviews and investigations are largely completed: Gas to Power: The company has identified two access points into the local electricity transmission grids. The first with 2MW capacity is located with 300m of the L7 wellsite. The second with 4MW capacity is located approximately 1km from the L7 wellsite. Horizon has made an application to secure the 2MW capacity that will be the first tie-in point for G2P. The company continues to work towards securing the 4MW at the second location. The preliminary design of the gas processing facility that will be required to separate the liquid condensate and any free water from the L7 gas stream has been completed. The Company has commenced sourcing the required vessels and other process equipment. Work on the EIA for the production facility is underway targeting submission in mid-June. Full Field Development Plan The Company has commenced the preliminary work for the EIA for the planned 100km2 3D seismic survey over the Lachowice gas field. A third-party evaluation has identified a high-pressure gas network tie-in point approximately 14 km northeast of L7, half the distance of the previous plan, which will result in reduced pipeline costs and faster approvals. Takeaway capacities have been confirmed and are consistent with Horizon's short and long-term forecast production volumes. The Company has commenced discussions with pipeline operator and owner to secure access and pipeline capacity. The Company will shortly commence the initial work on the EIA for the full field development facility site and commence the process to rezone the land for industrial use. Lachowice 7 Well Workover Operations Program The L7 workover is scheduled to be conducted in September/October of this year subject to receiving the necessary long lead items, equipment and services as planned. A detailed program has been completed and application to the Polish Mining authority for the program will be submitted shortly. The workover program will consist of: Upgrade the wellhead to execute the workover and eventual production. Drill out a surface cement plug and downhole mechanical plug in the wellbore. Pressure test the existing well casing to ensure wellbore security and integrity Drill and recover an existing packer located above the zone that originally tested up to 8.9mmscf/d gas Reperforate, acid stimulation and production test of this same zone Complete the well for production in anticipation of the EPF to be installed on site in first half 2026. The Company is targeting gas/electricity sales and first cash flow by the first half of 2026. About Horizon Petroleum Ltd. Calgary-based Horizon is focused on the appraisal and development of natural gas and oil reserves in Europe. The Management and Board of Horizon consist of oil & gas professionals with significant international experience. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains "forward-looking statements" or "forward-looking information" (collectively referred to herein as "forward-looking statements") within the meaning of applicable securities legislation. Such forward-looking statements include, without limitation, forecasts, estimates, expectations and objectives for future operations that are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Horizon. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur or be achieved. This press release contains forward-looking statements pertaining to, among other things the timing of re-entry of the well, the moving of the infrastructure in the area, timing of sales gas, and other operational matters in this news release, all of which are subject to change. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Horizon and described in the forward-looking information contained in this press release. Although Horizon believes that the material factors, expectations and assumptions expressed in such forward-looking statements are reasonable based on information available to it on the date such statements were made, no assurances can be given as to future results, levels of activity and achievements and such statements are not guarantees of future performance. View original content to download multimedia: SOURCE Horizon Petroleum Ltd. Sign in to access your portfolio
Business Upturn
12 hours ago
- Business Upturn
OWNx Honors U.S. Military with Free Access to Wholesale Gold, Silver, and Platinum
Lawrence, KS , June 01, 2025 (GLOBE NEWSWIRE) — In a bold extension of its mission to make precious metals more accessible to everyone, OWNx today announced an exclusive new initiative: all active-duty military personnel and U.S. military veterans are now eligible to receive the OWNx EDGE™ Membership completely free, gaining access to gold, silver, and platinum at wholesale cost with zero transaction or membership fees. OWNx This unprecedented offer reinforces OWNx's commitment to financial empowerment through transparency, trust, and innovation—values deeply aligned with those of the military community. 'We believe that those who serve our country deserve every opportunity to build and protect their wealth with confidence and integrity,' said Josh McCleary, Co-Founder and COO of OWNx. 'Offering EDGE membership at no cost is our way of saying thank you and ensuring that service members and veterans can access precious metals without unnecessary fees or barriers.' Industry-First Access—Now Free for Military and Veterans The OWNx EDGE™ membership—launched in April 2025—remains the first and only program of its kind in the precious metals industry. Investors typically pay $14.99 monthly or $149 annually for EDGE access. It allows members to buy fractional or whole ounces of physical gold, silver, and platinum at cost, without retail markups or hidden spreads that can range from 5-25% above spot price at traditional dealers. For the military and veteran community, this program is now entirely free for life, with no monthly charges, no commissions, and no administrative fees. Real Investment Impact for Those Who Served The savings from eliminating both membership fees and markups are substantial for military families building wealth. A $25,000 investment in gold with traditional dealers could incur $875 to $2,500 in hidden fees and markups. With free OWNx EDGE for military members, service members and veterans pay nothing beyond the actual cost of the metals, allowing them to put up to $2,400 more into actual precious metals compared to alternatives. Eligible military members and veterans gain: Access to wholesale pricing on gold, silver, and platinum with zero markup No membership fees, account fees, or transaction fees—ever. There is just a small one-time fee of $5 to cover the cost of military verification. Fractional ownership access to low-premium large bars without minimum purchase requirements Secure, insured storage in non-bank depositories in Delaware or Texas at just 0.6% per year (0.5% for IRA holdings) Easy, automated savings tools to build metal holdings over time User-friendly platform with seamless online dashboard and mobile app Full ownership of allocated metals with optional physical delivery (additional shipping costs apply) IRA integration available with OWNx Precious Metals IRA OWNx Built on Trust. Delivered with Purpose. OWNx has long been recognized for its commitment to transparency, client protection, and simplicity—offering a secure way for individuals to diversify into precious metals without hype, pressure, or opaque pricing models. Now, with this new initiative, OWNx further expands its reach to those who have served and sacrificed for the nation. The enrollment process is straightforward: military personnel and veterans can verify their service status at using standard military documentation (DD-214 for veterans, military ID for active duty) to claim their free lifetime EDGE membership. 'With this offer, we're not just waiving fees—we're opening the door to a stronger, fairer financial future,' added McCleary. 'We're honored to support the military community with the tools and transparency they deserve, giving them access to the same institutional pricing that was previously available only to bulk purchasers.' About OWNx Founded in 2008, OWNx is a pioneering platform in the precious metals market, offering secure and innovative solutions for those looking to invest in gold, silver, and platinum. With a focus on technology-driven solutions, OWNx has transformed how individuals access precious metals by providing automatic purchase options, secure storage, and instant trading capabilities, empowering people to diversify their portfolios with confidence. The company's OWNx Precious Metals IRA allows investors to include physical precious metals in their retirement planning while enjoying the benefits of EDGE membership. For more information about us, check out OWNx reviews or Military personnel and veterans can learn more about the free EDGE membership offer at ### Contact Information Josh McClearyCo-Founder and COO [email protected] Lawrence, Kansas
